<unk>  consists of the humanized monoclonal antibody<unk>  (against CD22), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin. Ozogamicin is N-acetyl-gamma-calicheamicin dimethylhydrazide. It includes the same linker, called "AcBut", and toxin, as gemtuzumab ozogamicin, which arose from the same collaboration. The linker is a carbonyl-containing carboxylic acid. The antibody, originally called G5/44, was created by grafting the complementarity-determining regions and some framework residues from the murine anti-CD22 mAb m5/44, onto human acceptor frameworks.
Inotuzumab ozogamicin
Ranibizumab
Gemtuzumab ozogamicin
Bevacizumab
Ponatinib
Sorafenib
Ruxolitinib
Erdafitinib